{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(1)"],"submitter":["Wang Y"],"pubmed_abstract":["<h4>Background</h4>Poor graft function (PGF) or prolonged isolated thrombocytopenia (PT), which are characterized by pancytopenia or thrombocytopenia, have become serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our previous single-arm trial suggests that N-acetyl-L-cysteine (NAC) prophylaxis reduced PGF or PT after allo-HSCT. Therefore, an open-label, randomized, phase 3 trial was performed to investigate the efficacy and tolerability of NAC prophylaxis to reduce PGF or PT after allo-HSCT.<h4>Methods</h4>A phase 3, open-label randomized trial was performed. Based on the percentage of CD34<sup>+</sup>VEGFR2 (CD309)<sup>+</sup> endothelial cells (ECs) in bone marrow (BM) detected by flow cytometry at 14 days before conditioning, patients aged 15 to"],"journal":["BMC medicine"],"pagination":["140"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9044574"],"repository":["biostudies-literature"],"pubmed_title":["Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial."],"pmcid":["PMC9044574"],"pubmed_authors":["Zhang YY","Zhang XH","Huang XJ","Zhao HY","Xu LP","Liu KY","Wang Y","Kong Y","Wang YZ"],"additional_accession":[]},"is_claimable":false,"name":"Prophylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.","description":"<h4>Background</h4>Poor graft function (PGF) or prolonged isolated thrombocytopenia (PT), which are characterized by pancytopenia or thrombocytopenia, have become serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our previous single-arm trial suggests that N-acetyl-L-cysteine (NAC) prophylaxis reduced PGF or PT after allo-HSCT. Therefore, an open-label, randomized, phase 3 trial was performed to investigate the efficacy and tolerability of NAC prophylaxis to reduce PGF or PT after allo-HSCT.<h4>Methods</h4>A phase 3, open-label randomized trial was performed. Based on the percentage of CD34<sup>+</sup>VEGFR2 (CD309)<sup>+</sup> endothelial cells (ECs) in bone marrow (BM) detected by flow cytometry at 14 days before conditioning, patients aged 15 to","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-05-09T19:18:38.86Z","creation":"2025-04-25T18:07:25.071Z"},"accession":"S-EPMC9044574","cross_references":{"pubmed":["35473809"],"doi":["10.1186/s12916-022-02338-9"]}}